|
Originally published In Press as doi:10.1074/jbc.M201304200 on July 3, 2002
J. Biol. Chem., Vol. 277, Issue 37, 34322-34328, September 13, 2002
The Krüppel-like Factor KLF15 Regulates the
Insulin-sensitive Glucose Transporter GLUT4*
Susan
Gray ,
Mark W.
Feinberg ,
Sarah
Hull ,
Chay T.
Kuo§,
Masafumi
Watanabe ,
Sucharita Sen
(Banerjee) ,
Ana
DePina ,
Richard
Haspel , and
Mukesh K.
Jain ¶
From the Cardiovascular Division, Brigham and
Women's Hospital, Boston, Massachusetts 02115 and the
§ Pritzker School of Medicine, The University of Chicago,
Chicago, Illinois 60637
Received for publication, February 7, 2002, and in revised form, May 23, 2002
 |
ABSTRACT |
Resistance to the stimulatory effects of insulin
on glucose utilization is a key feature of type 2 diabetes, obesity,
and the metabolic syndrome. Recent studies suggest that insulin
resistance is primarily caused by a defect in glucose transport. GLUT4
is the main insulin-responsive glucose transporter and is expressed predominantly in muscle and adipose tissues. Whereas GLUT4 has been
shown to play a critical role in maintaining systemic glucose homeostasis, the mechanisms regulating its expression are incompletely understood. We have cloned the murine homologue of KLF15, a member of
the Krüppel-like family of transcription factors. KLF15 is highly
expressed in adipocytes and myocytes in vivo and is induced when 3T3-L1 preadipocytes are differentiated into adipocytes. Overexpression of KLF15 in adipose and muscle cell lines potently induces GLUT4 expression. This effect is specific to KLF15 as overexpression of two other Krüppel-like factors,
KLF2/LKLF and KLF4/GKLF, did not induce GLUT4 expression. Both basal
(3.3-fold, p < 0.001) and insulin-stimulated
(2.4-fold, p < 0.00001) glucose uptake are increased
in KLF15-overexpressing adipocytes. In co-transfection assays, KLF15
and MEF2A, a known activator of GLUT4, synergistically activates the
GLUT4 promoter. Promoter deletion and mutational analyses provide
evidence that this activity requires an intact KLF15-binding site
proximal to the MEF2A site. Finally, co-immunoprecipitation assays show
that KLF15 specifically interacts with MEF2A. These studies indicate
that KLF15 is an important regulator of GLUT4 in both adipose and
muscle tissues.
 |
INTRODUCTION |
Glucose uptake into cells is regulated by two families of cellular
transporters, the sodium-linked glucose transporters (kidney, intestine) and the facilitated glucose transporters (GLUTs). With respect to the latter, GLUT4 is the main effector of insulin-stimulated glucose transport and is located primarily in muscle and adipose tissues (1).
Clinical and experimental observations suggest that insulin-stimulated
glucose transport via GLUT4 is critical in maintaining systemic glucose
homeostasis. For example, heterozygous mice deficient in GLUT4 exhibit
muscle insulin resistance and develop diabetes (2). Tissue-specific
disruption of GLUT4 in adipose tissue and skeletal
muscle results in the development of insulin resistance and glucose
intolerance (3, 4). In human type 2 diabetic patients, impairment of
insulin-stimulated glucose transport is responsible for resistance to
insulin-stimulated glycogen synthesis in muscle (5-7).
Studies in adipose and muscle tissues reveal that
expression of the GLUT4 glucose transporter is controlled at the level
of transcription (8, 9). In vitro and in vivo
promoter studies support a role for members of the MADS-box family of
transcription factors termed MEF2 proteins in the regulation of the
GLUT4 promoter. However, these studies suggest that MEF2 binding alone
is not sufficient to fully support GLUT4 expression (10-12).
The Krüppel-like family of transcription factors are
important regulators of cellular development, differentiation, and
activation. The KLFs are a subfamily of
Cys2/His2 zinc finger DNA-binding proteins
related to the Drosophila melanogaster segmentation gene product, Krüppel. Previous studies demonstrate a critical role for this family in erythropoiesis (KLF1/EKLF) (13, 14), T cell
activation (KLF2/LKLF), vascular development (KLF2/LKLF) (15, 16), lung
development (17, 18), and skin development (KLF4/GKLF/EZF) (19). We
identified a novel member of this family termed KLF15 and provide
evidence that it regulates GLUT4 expression in both adipose and muscle cells.
 |
MATERIALS AND METHODS |
Reagents--
The heart cDNA library was obtained from
Stratagene. Reagents for 3T3-L1 differentiation,
3-isobutyl-1-methylxanthine, dexamethasone, and insulin as well
as nonradioactive 2-deoxy-D-glucose and cytochalasin B for
glucose uptake assays were purchased from Sigma. The 3T3-L1, A10,
NIH-3T3, and C2C12 cells were obtained from American Type Culture
Collection. Neonatal rats and pups were obtained from Taconic Farms.
Mice for aortic banding experiments were obtained from Charles River
Laboratories. ES cells were obtained from Incyte. MEF2A expression
construct was kindly provided by E. Olson (University of Texas, Southwestern).
Cloning of KLF15--
The C-terminal zinc finger region of
KLF1/EKLF was used as a probe to screen a mouse embryonic cDNA
library under low-stringency conditions. A partial clone of KLF15 was
obtained and used to screen a mouse heart cDNA library to obtain
the full-length clone. Both strands of the full-length clone were
sequenced by the dideoxy chain termination method.
Cell Culture--
3T3-L1 differentiation was performed as
previously described (20). Briefly, 3T3-L1 cells were grown in 10%
FCS1/DMEM and media
was changed to 10% FCS/DMEM supplemented with 3-isobutyl-1-methylxanthine, dexamethasone, and insulin
(differentiation medium) at 2 days post-confluence ("day 0"). After
48 h, media was changed to 10% FCS/DMEM supplemented with
1/4 the concentration of insulin used at day 0. After 48 additional hours, cells were maintained in 10% FCS/DMEM. C2C12
myoblasts were cultured in 10% FBS/DMEM. Differentiation was induced
post-confluence using 2% horse serum/DMEM that was changed daily. A10
cells were cultured in 20% FBS/DMEM; NIH-3T3 fibroblasts were cultured
with differentiation medium to day 11 as described for 3T3-L1 cells.
For retroviral studies, the indicated cDNA was cloned into the
retroviral vector green fluorescent protein-RV (gift K. Murphy) and
retrovirus were generated as described (21). For infection of target
cells, retroviral supernatant and culture medium (10% FCS/DMEM + 4 µg/ml Polybrene) were mixed at a 1:1 ratio and added to preconfluent cells. Within 24-48 h nearly 100% infectivity was noted by assessment for green fluorescent protein. 2-Deoxy-D-glucose uptake
assays in 3T3-L1 cells were performed as described previously (22).
Electrophoretic Mobility Shift Assays--
The zinc finger
region of KLF15 bearing an N-terminal FLAG tag was generated by PCR and
cloned into the expression vector pCDNA3 (Invitrogen). Gel-shift
studies were performed as previously described (23).
Cardiomyocyte Isolation and Hypertrophy Studies--
Primary
neonatal rat ventricular cardiomyocytes were isolated as previously
described (24). Cardiomyocyte quiescence was induced in DMEM
supplemented with insulin, transferrin, and selenium. Cardiac
hypertrophy was induced by aortic banding of the proximal aorta as
previously described (25). Ventricles were harvested at 3 weeks after banding.
Antibody Generation, Immunohistochemistry, and -Galactosidase
Staining--
An anti-peptide antibody to the C-terminal 14 amino
acids was generated by Zymed Laboratories. Formalin-fixed and
paraffin-embedded tissues were stained using a 1:250 dilution of the
primary antibody with horseradish peroxidase-linked secondary antibody.
For -galactosidase staining, tissues were removed and fixed in
1.25% PBS/glutaraldehyde at room temperature for 10 min, rinsed
several times in PBS, and stained overnight at 37 °C in the dark.
Tissues were rinsed in PBS and dehydrated in ethanol before sectioning.
Generation of KLF15 +/ LacZ Mice--
The murine
KLF15 genomic clone was obtained by hybridization of a mouse
129SVJ library with an EcoRI-BamHI cDNA
fragment from the mouse KLF15 coding region. The targeting vector was
generated by inserting a 3-kb SmaI-EcoRI genomic
fragment from the first intron into the BamHI (blunt) and
EcoRI sites of pPNT (26) followed by simultaneous insertion
between pPNT NotI and XhoI sites of a 3.6-kb
HindIII-XhoI fragment containing a nuclear
lacZ gene (27) and a 3.5-kb genomic fragment extending from
the genomic NotI site to an engineered HindIII
site at the KLF15 ATG. The resulting targeting construct was
linearized with NotI before electroporation into 129SVJ ES
cells. Neo-resistant transfectants were selected by growth in G418 (200 µg/ml) and ganciclovir (1 µM). DNA from ES cell
clones was digested with BamHI, Southern blotted, and
hybridized with a 1.5-kb genomic fragment located 3' of the knockout
construct. ES cells from two independently derived KLF15
+/ clones were microinjected into C57BL/6 donor blastocysts that were
implanted into pseudopregnant females. The resulting male chimeras were
mated with C57BL/6 females and the agouti offspring were genotyped
using Southern analysis.
Co-immunoprecipitation Studies--
293T cells were transfected
with the indicated expression vectors. 48 h post-transfection the
cells were rinsed with PBS and harvested in 300 µl of RIPA buffer per
10-cm dish. Cellular debris was pelletted and the lysates were
subjected to immunoprecipitation with either 4 µg of -FLAG M2
monoclonal antibody or 4 µg of IgG1 control antibody
(Sigma) for 2 h at 4 °C after which protein A/G-Sepharose was
added (O/N, 4 °C). The beads were washed in RIPA buffer followed by
PBS and proteins were separated by SDS-PAGE.
Western Analysis--
Membranes were probed with MEF-2 (C-21)
polyclonal primary antibody (Santa Cruz) diluted at 1:300 followed by
rabbit-horseradish peroxidase secondary (Amersham
Biosciences) diluted 1:2000. Membranes were stripped and probed
with -FLAG M2 (Sigma) diluted 1:4000 followed by mouse-horseradish peroxidase secondary (Amersham Biosciences) diluted
1:5000.
 |
RESULTS |
Identification and Characterization of KLF15--
A partial
cDNA fragment of KLF15 was identified through a low stringency
homology screen of a mouse embryonic cDNA library using the zinc
finger region of EKLF as a probe. The full-length cDNA
was subsequently obtained by screening of a heart cDNA library. Analysis of the open reading frame revealed that KLF15 is a 415-amino acid protein with three Cys2/His2 zinc fingers
at the C terminus. The N terminus was notable for a discrete glutamic
acid-rich region (Fig.
1A, underlined). A
putative nuclear localization signal was present at amino acid 369 (-RHRR-). A GenBankTM search revealed that our factor is
the mouse homolog of a recently identified rat cDNA termed KKLF
(28). Based upon the recommendation of the Mouse and Human Nomenclature
Committee we refer to this factor as KLF15.

View larger version (37K):
[in this window]
[in a new window]
|
Fig. 1.
Sequence and expression of KLF15 in mouse
tissues. A, deduced amino acid sequence of KLF15. The
three zinc finger regions are in bold. The glutamic acid-rich region is
underlined. B, Northern analysis of KLF15
expression in mouse tissues. The size of the KLF15 mRNA is ~2.3
kb. C, cellular localization of KLF15. An affinity purified
antibody was raised against the C-terminal 14 amino acids of KLF15
(Zymed Laboratories). Immunohistochemical studies on white adipose
tissue were performed using a 1:250 dilution of the primary antibody
with horseradish peroxidase-linked secondary antibody. Counterstaining
was performed with eosin. Magnification ×1000. Arrows
indicate nuclear staining. KLF15lacZ +/ mice were
generated as described under "Materials and Methods."
5-Bromo-4-chloro-3-indolyl- -D-galactopyranoside
(X-gal) staining reveals expression in adipocytes, skeletal
myocytes, cardiomyocytes, and smooth muscle cells in a small blood
vessel. Counterstaining was performed using eosin. Magnification was
×1000 for all tissues except blood vessel (×400).
|
|
Northern analysis of mouse tissues showed KLF15 expression levels to be
the highest in adipose, muscle tissues (heart, skeletal muscle, and
aorta), kidney, and liver (Fig. 1B and data not shown). To
define the cellular expression of the KLF15 protein, an anti-peptide antibody was generated to the C-terminal 14 amino acids (Zymed Laboratories). This antibody was able to detect a single band using a
KLF15 in vitro transcribed and translated product (data not
shown). Immunohistochemical studies in adipose tissue reveal a punctate
pattern of nuclear staining in adipocytes from white fat (Fig.
1C, left panel). To further assess its expression
pattern and function we initiated efforts to generate mice deficient in KLF15 by homologous recombination. The knockout strategy included insertion of a nuclear lacZ gene at the KLF15
ATG. Assessment of -galactosidase activity in KLF15
LacZ+/ heterozygous mice demonstrated staining in adipocytes,
cardiomyocytes, skeletal myocytes, and smooth muscle cells (Fig.
1C, right panels).
KLF15 Induces GLUT4 Expression and Glucose Uptake in 3T3-L1
Cells--
KLF15 was highly expressed in adipose tissue. Given the
availability of cell lines that faithfully recapitulate adipogenesis in vitro, we assessed the expression of KLF15 during 3T3-L1
differentiation. Stimulation of these cells with an empirically derived
prodifferentiation mixture leads to a characteristic pattern of
induction for various transcription factors and target genes involved
in adipogenesis and lipogenesis (29). As shown in Fig.
2A, KLF15 mRNA was first detected by Northern analysis at day 3 of differentiation subsequent to
the induction of peroxisome proliferator-activated receptor (PPAR) ,
a critical regulator of adipogenesis. Comparison of KLF15
expression to a number of other genes induced during 3T3-L1 differentiation demonstrates an expression pattern most similar to that
of GLUT4. To further investigate the function of KLF15, we retrovirally
infected 3T3-L1 cells with either full-length KLF15 (KLF15), empty
vector (EV), or deletion mutants lacking either the N-terminal 56 or
200 amino acids of KLF15 (KLF15 56 and KLF15 200) and then
differentiated the cells for 4 days. In comparison to EV-infected
cells, we noted a marked induction of GLUT4 mRNA in KLF15
overexpressing cells. No effect on GLUT4 expression was seen in the
KLF15 56 mutant (data not shown). In contrast, KLF15 200 cells
exhibited a reduction in GLUT4 mRNA consistent with a dominant
negative effect (Fig. 2B). A modest effect was also noted on
fatty acid synthase and CCAAT/enhancer-binding protein family
(C/EBP ) expression along with minimal effects on the expression of
PPAR and fatty acid-binding protein.

View larger version (51K):
[in this window]
[in a new window]
|
Fig. 2.
KLF15 expression in 3T3-L1 cells and effects
on GLUT4 expression and glucose uptake. A, KLF15 mRNA is
induced during 3T3-L1 differentiation. 3T3-L1 cells were induced to
differentiate using hormonal agents as described under "Materials
and Methods." Cells were harvested at the indicated number of days
post-induction, and total RNA was isolated and subjected to Northern
analysis using the indicated probes. B, overexpression of
KLF15 induces GLUT4. 3T3-L1 cells were retrovirally infected with
either full-length cDNA (KLF15), EV, or a mutant lacking the
N-terminal 200 amino acids (KLF15 200) and
differentiated to day 4. Total RNA was isolated and subjected to
Northern analysis using the indicated probes. C, induction
of GLUT4 is specific to KLF15. 3T3-L1 cells were retrovirally infected
with KLF4, KLF2, EV, or KLF15 and differentiated to day 4. Northern
analysis was performed using a GLUT4 probe. D, KLF15 induces
glucose uptake. 3T3L1 cells were infected with KLF15 200, EV, or
KLF15 retrovirus and differentiated to day 6. The cells were cultured
without serum for 5 h before addition of 100 nM
insulin (shaded bars, +I) for 15 min. The cells
were washed and glucose transport assays were performed as described
under "Materials and Methods." Results are shown after
subtracting counts taken in the presence of the transport inhibitor
cytochalasin B and dividing by the total protein concentrations.
Results are normalized to the EV value in the absence of insulin
(n = 4). * = p < 0.007; ** = p < 0.001, compared with the ( )insulin EV value); = p < 0.008;  = p < 0.00001, compared with the (+)insulin EV value).
|
|
To determine whether the induction of GLUT4 mRNA was a specific
result of KLF15 overexpression, we tested the ability of two additional
members of the Krüppel-like family, KLF2/LKLF and KLF4/GKLF, to
affect GLUT4 levels. 3T3-L1 cells were retrovirally infected with EV,
KLF2, KLF4, or KLF15, differentiated to day 4, and then harvested for
total RNA. Northern blot analysis using a GLUT4 probe demonstrated that
only KLF15 was able to induce GLUT4 mRNA above the level found in
EV-infected cells. In contrast, both KLF2 and KLF4 reduced GLUT4
expression (Fig. 2C).
To assess the functional consequence of KLF15-mediated GLUT4 induction,
we performed [3H]2-deoxyglucose uptake assays in 3T3-L1
in the presence and absence of insulin. As shown in Fig. 2D,
compared with EV-infected cells, KLF15 overexpressing cells exhibited a
3.3-fold increase in basal glucose uptake (p < 0.001),
whereas KLF15 200 expressing cells showed a 25% reduction in glucose
uptake (p < 0.007). Following insulin stimulation, we
observed a 2.5-fold increase in glucose uptake in KLF15 overexpressing
cells compared with EV-infected cells (p < 0.00001),
whereas KLF15 200 expressing cells showed a 40% reduction in glucose
uptake (p < 0.008). The fact that KLF15 200-, EV-,
and KLF15-infected cells all showed a ~3-fold increase in the amount
of glucose taken up in response to insulin (Fig. 2D, compare
the shaded bar to white bar for each construct)
suggests that KLF15 does not sensitize cells to insulin. However, by
augmenting the level of GLUT4 in 3T3-L1 cells, KLF15 overexpression
does result in an increase in both basal and insulin-stimulated glucose uptake.
KLF15 Induces GLUT4 in Muscle Cell Lines--
In addition to
adipose tissue, GLUT4 expression is also seen in all muscle cells, both
striated (skeletal and cardiac muscle) and smooth muscle (blood
vessel). To assess the role of KLF15 in skeletal muscle cells, we used
C2C12 cells as a model system. Interestingly, it is recognized that
virtually all muscle cell lines are deficient in GLUT4 expression (12).
Indeed, we were unable to detect either GLUT4 or KLF15 mRNA by
Northern analyses using 20 µg of total RNA (data not shown). To
assess whether the deficiency of KLF15 in C2C12 may account for the
absence of GLUT4 in this cell line, we retrovirally overexpressed KLF15
in C2C12 cells. As shown in Fig.
3A, overexpression of KLF15 in
C2C12 cells robustly induced GLUT4 mRNA. This effect was specific
as another glucose transporter, GLUT1, was not induced. In addition,
KLF15 overexpression induced GLUT4 mRNA in NIH-3T3 fibroblasts and
A10 cells (a smooth muscle cell line; Fig. 3B).

View larger version (44K):
[in this window]
[in a new window]
|
Fig. 3.
Role of KLF15 in muscle cells.
A-E show Northern analyses with the probes indicated at the
left of each panel. A, KLF15 induces GLUT4
mRNA in C2C12 cells. C2C12 cells were infected with EV or KLF15
(KLF) retrovirus and maintained in high serum (10% FCS)
until confluent. The cells were then either harvested (myoblast) or
switched to differentiation medium (2% horse serum) and cultured for
an additional 5 days (myotube). B, KLF15 induces GLUT4 in
smooth muscle and fibroblast cell lines. Preconfluent NIH-3T3
fibroblasts and A10 smooth muscle cells were infected with EV or KLF15
retrovirus. The fibroblasts were treated with hormonal inducing agents
and harvested 11 days after induction. The A10 cells were harvested
72 h after infection. C, KLF15 mRNA is induced in
the postnatal mouse heart. Total RNA was harvested from ventricles of
C57BL/6 mice on the indicated postnatal day and subjected to Northern
analysis. Ribosomal hybridization with 28 S is shown to indicate
loading. D, KLF15 is expressed in neonatal cardiomyocytes.
Cardiomyocytes were harvested from 2-day-old rat neonatal pups and
cultured under growing (G; 10% FCS) or quiescent conditions
(Q; 0% FCS + insulin, transferrin, and selenium).
E, KLF15 mRNA levels are reduced with cardiac
hypertrophy. Eight-week-old mice were subjected to aortic banding or
sham operation. Ventricles were harvested 3 weeks after banding and
total was RNA isolated. Each number represents an individual
animal.
|
|
Glucose is an important source of energy for the heart at rest. The
heart becomes increasingly dependent on glucose under certain
physiologic and pathologic states such as exercise, hyperthyroidism, and hypertrophy (30). GLUT4 expression in the rodent heart is induced
during the first few weeks after birth and is accompanied by a
concomitant decrease in GLUT1 expression (9, 31). We compared the
expression pattern of KLF15 and GLUT4 in the postnatal mouse heart as
well as after the induction of cardiac hypertrophy. Total RNA from
mouse ventricles was harvested at various time points after birth and
subjected to Northern analysis (Fig. 3C). We observed very
low levels of KLF15 mRNA at postnatal days 3 and 10 that increased
by day 15 and reached near adult levels by day 20. This pattern of
expression is similar to that of GLUT4 and correlates inversely with
cyclin A, a marker of cellular growth known to decrease during the
postnatal period (32). Isolation of neonatal cardiomyocytes and culture
under quiescent conditions confirmed both KLF15 and GLUT4 expression in
cardiomyocytes (Fig. 3D). Finally, previous studies show
that GLUT4 levels are reduced following the induction of cardiac
hypertrophy (33). To assess KLF15 expression under these conditions, we
used aortic banding to induce pressure-overload hypertrophy in
8-week-old C57BL/6 mice and harvested the total ventricle RNA 3 weeks after banding. In contrast to sham operated animals, the banded
animals showed a reduction in the levels of both KLF15 and GLUT4
mRNA (Fig. 3E). Taken together these data support a role
for KLF15-mediated regulation of GLUT4 in muscle tissues.
KLF15 Binds DNA and Transactivates the GLUT4 Promoter--
Members
of the Krüppel-like family bind to specific DNA elements
(5'-CNCCC-3') to exact their function. To assess the ability of KLF15
to bind DNA we performed electrophoretic mobility shift assays using
FLAG-tagged KLF15 and a probe containing the consensus sequence
(5'-CACCC-3'). As shown in Fig.
4A, a single DNA-protein complex was seen. This complex was specific as it can be competed by an
identical but not a nonspecific (5'-CATGTG-3') or mutated (5'-CACCG-3')
oligomer. Finally this complex can be supershifted with an anti-FLAG
antibody but not with an unrelated antibody (IgG). Thus, KLF15 was able
to bind the KLF consensus sequence.

View larger version (27K):
[in this window]
[in a new window]
|
Fig. 4.
KLF15 transactivates the GLUT4 promoter.
A, KLF15 binds the CACCC element. In vitro
translated, FLAG-tagged KLF15 was incubated with a
32P-labeled oligomer containing the wild type CACCC-binding
site or plus one of the following cold competitor probes: nonspecific,
CACCC mutant, or increasing amounts of wild type CACCC. A single
dominant DNA-protein complex was seen. Competition and supershift (*)
studies verified that the dominant complex was specific for KLF15-CACCC
binding. Electrophoretic mobility shift assays were performed as
described under "Materials and Methods." B, schematic
diagram of the GLUT4 promoter. Potential KLF-binding sites are
represented as shaded rectangles. C, KLF15 induces the GLUT4
promoter. NIH-3T3 cells were transfected with the indicated GLUT4
promoter and either the EV or KLF15 expression construct. The molar
ratio of reporter to expression plasmid was 1:2.5. Luciferase and
-galactosidase assays were performed. Results are expressed as -fold
induction compared with vector alone (n = 6-9 per
group). * = p < 0.0001 compared with the respective
empty vector; = p < 0.001 compared with the empty
vector value on the 500-bp promoter; ** = p < 0.001 compared with the KLF15 vector value on the 813-bp wild type
promoter.
|
|
To define the mechanism(s) underlying the ability of KLF15 to induce
GLUT4 expression, we performed transient transfection studies using
deletion constructs of the GLUT4 promoter. Previous studies in
transgenic mice have demonstrated that the proximal 895 bp of the GLUT4
promoter was sufficient to recapitulate endogenous expression and that
a proximal regulatory region ( 412 > 526) is essential. Within
this region lies a consensus binding site for myocyte enhancer factors
(MEFs). Mutation of the MEF site results in loss of GLUT4 promoter
activity in transgenic animals (Fig. 4B) (10, 11, 34).
Analysis of the 895-bp GLUT4 promoter revealed several potential
KLF15-binding sites (shaded boxes; Fig. 4B). One
of these sites ( 499 503) lies in close proximity to the
MEF-binding element ( 454 464). We observed an ~8-9-fold
(p < 0.0001) induction of both the 2.2-kb and 813-bp
GLUT4 promoter constructs by KLF15 (Fig. 4C). Approximately
two-thirds of this induction was eliminated with the 500-bp GLUT4
promoter (~3.5-fold induction; p < 0.001); the
remainder of the activity was completely eliminated with the 149-bp
promoter fragment (~1.5-fold induction; p < 0.1). To
determine which potential KLF-binding site between base pairs
500 813 was responsible for the loss of transactivation,
we introduced a point mutation at the 499-bp position
(CACCC CACCG) because this site was closest to
the MEF element and is contained within the proximal regulatory region.
This single base pair mutation in the 813-bp promoter resulted in a
loss of transactivation similar to that of the 500-bp promoter (Fig.
4C). These data suggest that KLF15 can transactivate the
GLUT4 promoter by binding near the MEF2 consensus site.
KLF15 and MEF2A Synergistically Transactivate the GLUT4
Promoter--
The proximity of the KLF15- and MEF-binding sites raised
the possibility that these two factors may function in a coordinated manner to induce the GLUT4 promoter. To assess this possibility, we
performed co-transfection studies. As shown in Fig.
5A, we observed that the
combination of KLF15 and MEF2A resulted in a synergistic activation of
the 813-bp GLUT4 promoter (~13-fold; p < 0.0001 by
comparison to KLF15 alone). This synergistic effect was not seen in the
500-bp GLUT4 promoter that lacks the KLF15-binding site (Fig.
5A, right panel). These studies suggest that
KLF15 can induce the GLUT4 promoter and this may occur through a
coordinated effort with MEF2A.

View larger version (28K):
[in this window]
[in a new window]
|
Fig. 5.
KLF15 and MEF2A cooperate to induce GLUT4
promoter activity. A, KLF15 functions synergistically with
MEF2A. The 813- and 500-bp GLUT4 promoter reporters were each
transfected with EV, KLF15, MEF2A, or both KLF15 and MEF2A expression
constructs. Luciferase and -galactosidase assays were performed.
Cotransfection studies were performed using a 1:1 ratio of reporter to
expression plasmid (n = 6 per group), * = p < 0.001 compared with KLF15. B, KLF15
interacts with MEF2A in cells. 293T cells were transfected with
expression vectors for MEF2A + empty pcDNA3, MEF2A + FlagKLF15, or
MEF2A + FlagKLF4. Total cell lysates were collected 48 h
post-transfection and subjected to immunoprecipitation with an -FLAG
monoclonal antibody or an IgG1 isotype control antibody
followed by Western analysis with -FLAG and MEF2A antibodies as
described under "Materials and Methods." The weak bands seen in
the -FLAG and IgG immunoprecipitation lanes are IgG proteins
recognized by the anti-mouse IgG secondary antibody used in the
-FLAG Western blot.
|
|
These data also raised the possibility that KLF15 and MEF2A
may interact directly to transactivate the GLUT4 promoter. To investigate this hypothesis, we cotransfected 293T cells with expression vectors for MEF2A and full-length FLAG-tagged KLF15, FLAG-KLF4, or empty vector (pCDNA3). An -FLAG antibody
immunoprecipitated MEF2A protein from the lysate of cells transfected
with FlagKLF15 and MEF2A, but not with empty vector + MEF2A or FlagKLF4 + MEF2A (Fig. 5B, left panel). This indicates
that KLF15 directly interacts with MEF2A. The specificity of this
interaction was further demonstrated by the fact that an
IgG1 isotype control antibody was unable to immunoprecipitate MEF2A (Fig. 5B, right
panel).
 |
DISCUSSION |
A number of disease states such as diabetes and obesity are
characterized by glucose intolerance and insulin resistance. Clinical and experimental observations suggest that a defect in glucose transport contributes to these conditions (5). Whereas decreased GLUT4
expression per se is not the cause of insulin resistance in
these diseases, previous studies show that enhanced GLUT4 levels can
augment insulin responsiveness and glucose tolerance (1, 35-38).
Indeed, glucose tolerance and insulin responsiveness are increased by
overproduction of GLUT4 in muscle and/or adipose tissue in both normal
and diabetic mice (35-39). These findings suggest that a better
understanding of the mechanisms regulating the insulin-sensitive
glucose transporter GLUT4 may ultimately lead to novel strategies for
the treatment of various insulin-resistance states. We provide in this
report evidence for KLF15 as an important regulator of GLUT4
gene expression.
Insulin-sensitive glucose transport is a late event in the process of
differentiation that characterizes a mature fat cell (40). Current
models of the transcriptional basis for adipocyte differentiation
highlight an interplay between members of two major families, the C/EBP
and PPAR families (41). Studies to date indicate that C/EBP and
C/EBP induce PPAR , an essential regulator of adipogenesis and
insulin-sensitive glucose uptake. The uptake of glucose in response to
insulin requires expression of components of the insulin signaling
pathway as well as GLUT4. PPAR induces C/EBP , which augments the
expression and phosphorylation of the insulin receptor and insulin
receptor substrate-1 (42). PPAR is also essential for GLUT4
expression (22, 43). It has been hypothesized that an additional factor
downstream of PPAR is also involved in the induction of GLUT4
(22).
C/EBP has also been implicated in the regulation of GLUT4
expression. For example, El-Jack and colleagues (40) found that reconstitution of insulin-sensitive glucose transport in fibroblasts requires expression of both PPAR and C/EBP . These authors found that in NIH-3T3 cells, the expression of C/EBP was required for GLUT4 expression (40). In contrast, several lines of evidence suggest
that C/EBP expression is not requisite for GLUT4 expression. For
example, C/EBP null mice do not exhibit any reduction in GLUT4
expression (44). More recently, Wu and colleagues (43) found that
reconstitution of C/EBP null cells with PPAR resulted in GLUT4
expression. Taken together, these data suggest that the role of
C/EBP remains controversial. Our data suggest that KLF15 may serve
as a downstream effector as it is expressed subsequent to PPAR and
is able to induce GLUT4. These data raise the possibility that during
the process of adipogenic differentiation both C/EBP and KLF15 may
function in a coordinated manner to confer full insulin responsiveness
to the adipocyte. C/EBP induces components of the insulin signaling
pathway, whereas KLF15 induces expression of GLUT4 (42, 43).
In addition to adipose, GLUT4 is highly expressed in muscle tissues
where it plays critical roles in glucose homeostasis and tissue
function. For example, loss of GLUT4 expression in skeletal muscle
leads to the development of hyperglycemia and insulin resistance (3).
In the heart, GLUT4 deficiency leads to death of the animal secondary
to the development of a cardiomyopathy (30). Finally, GLUT4 is
expressed in smooth muscle cells where it may be involved in the
regulation of smooth muscle cell contraction (45, 46). Given these
important functions for GLUT4 in muscle, we assessed the expression of
KLF15 in these tissues. We observed KLF15 expression in all
muscle cells in vivo (Fig. 1C). KLF15
overexpression induced GLUT4 expression in both skeletal and smooth
muscle cell lines (C2C12 and A10). Finally, KLF15 expression in
cardiomyocytes paralleled that of GLUT4 during the postnatal period and
in a disease model of left ventricular hypertrophy. It is noteworthy
that the effects of KLF15 bear similarity to those observed for the
transcriptional coactivator PGC-1 in muscle cell lines. Like KLF15,
PGC-1 induces GLUT4 expression in C2C12 cells, augments basal glucose
uptake, and functions in a cooperative manner with MEFs (12). Whether a
direct relationship exists between PGC-1 and KLF15 is currently under investigation.
GLUT4 mRNA and protein expression are subject to
complex regulation by a number of hormonal/metabolic influences and
physiologic states. A major form of regulation involves the
translocation of GLUT4 protein from the interior of cells to the plasma
membrane in response to insulin stimulation (reviewed in Ref. 1).
However, GLUT4 mRNA levels are also regulated in conditions such as
experimental diabetes and fasting (47, 48). In addition, Santalucia and co-workers (9) recently demonstrated that perinatal expression of
cardiac GLUT4 is controlled directly at the level of gene
transcription. Thus, an understanding of the mechanisms governing
GLUT4 gene expression has been of considerable interest. A
series of elegant promoter deletion analyses using transgenic
approaches demonstrate that the proximal 895 bp of the GLUT4 promoter
contains the necessary elements to recapitulate endogenous expression
of GLUT4 (10). These studies identify a proximal regulatory region that
contains a critical MEF-binding element (10, 34). This MEF site is necessary but not sufficient to support expression of the
GLUT4 gene, suggesting that other factors likely participate
(10). We found that KLF15 is able to strongly induce the GLUT4 promoter and that the majority of this activity was mediated by a binding site
that lies in proximity to the MEF site. The functional importance of
this was verified by cotransfection studies that revealed a synergistic
activation of the GLUT4 promoter by KLF15 and MEF2A. Finally, a direct
interaction between KLF15 and MEF2A is supported by
co-immunoprecipitation studies. Thus, our data add to the current understanding of the transcriptional control of GLUT4 expression and
support a coordinated effort by KLF15 and MEF2A. The generation of
KLF15 null mice or KLF15 and MEF2A double knockout mice will provide
further insights into the role of these factors in GLUT4 regulation.
These studies are currently in progress.
 |
ACKNOWLEDGEMENTS |
We thank Drs. Evan Rosen,
Guillaume Adelmant, and Thomas Michel for helpful advice and
review of this manuscript. We gratefully acknowledge the support of Dr.
Jeffrey M. Leiden in making these studies possible and Dr. Barbara Kahn
for critical advice (Metabolic Physiology Core Grant; DK57521).
 |
FOOTNOTES |
*
This work was supported by grants from The Damon
Runyon-Walter Winchell Cancer Research Fund (to S. G.), The
Charles A. King Trust (Fleet Asset Management, Co-trustee) (to S. G.), National Institutes of Health, NHLBI Grants K08HL03747 (to M. K. J.) and K08HL67755 (to M. W. F.) and American Heart
Association-grant-in-aid Grant 0060159T (to M. K. J.).The costs of publication of this article were defrayed in part by the
payment of page charges. The article
must therefore be hereby marked
"advertisement" in accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
The nucleotide sequence(s) reported in this paper has been submitted to the GenBankTM/EBI Data Bank with accession number(s) F317225.
¶
To whom correspondence should be addressed: Cardiovascular
Division, Brigham and Women's Hospital, Thorn Bldg., Rm. 1123, 20 Shattuck St., Boston, MA 02115. Tel.: 617-278-0142; Fax: 617-732-5132; E-mail: mjain@rics.bwh.harvard.edu.
Published, JBC Papers in Press, July 3, 2002, DOI 10.1074/jbc.M201304200
 |
ABBREVIATIONS |
The abbreviations used are:
FCS, fetal calf serum;
DMEM, Dulbecco's modified Eagle's medium;
PBS, phosphate-buffered saline;
PPAR, peroxisome proliferator-activated
receptor;
EV, empty vector;
MEF, myocyte enhancer factor;
C/EBP, CCAAT/enhancer-binding protein.
 |
REFERENCES |
| 1.
|
Shepherd, P. R.,
and Kahn, B. B.
(1999)
N. Engl. J. Med.
341,
248-257[Free Full Text]
|
| 2.
|
Stenbit, A.,
Tsao, T., Li, J.,
Burcelin, R.,
Greenen, D.,
Factor, S.,
Housenecht, K.,
Katz, E.,
and Charron, M.
(1997)
Nat. Med.
3,
1096-1101[CrossRef][Medline]
[Order article via Infotrieve]
|
| 3.
|
Zisman, A.,
Peroni, O. D.,
Abel, E. D.,
Michael, M. D.,
Mauvais-Jarvis, F.,
Lowell, B. B.,
Wojtaszewski, J. F.,
Hirshman, M. F.,
Virkamaki, A.,
Goodyear, L. J.,
Kahn, C. R.,
and Kahn, B. B.
(2000)
Nat. Med.
6,
924-928[CrossRef][Medline]
[Order article via Infotrieve]
|
| 4.
|
Abel, E. D.,
Peroni, O.,
Kim, J. K.,
Kim, Y. B.,
Boss, O.,
Hadro, E.,
Minnemann, T.,
Shulman, G. I.,
and Kahn, B. B.
(2001)
Nature
409,
729-733[CrossRef][Medline]
[Order article via Infotrieve]
|
| 5.
|
Cline, G. W.,
Petersen, K. F.,
Krssak, M.,
Shen, J.,
Hundal, R. S.,
Trajanoski, Z.,
Inzucchi, S.,
Dresner, A.,
Rothman, D. L.,
and Shulman, G. I.
(1999)
New Engl. J. Med.
341,
240-246[Abstract/Free Full Text]
|
| 6.
|
Shulman, G. I.,
Rothman, D. L.,
Jue, T.,
Stein, P.,
DeFronzo, R. A.,
and Shulman, R. G.
(1990)
N. Engl. J. Med.
322,
223-228[Abstract]
|
| 7.
|
Shulman, G. I.
(2000)
J. Clin. Invest.
106,
171-176[Medline]
[Order article via Infotrieve]
|
| 8.
|
Gerrits, P. M.,
Olson, A. L.,
and Pessin, J. E.
(1993)
J. Biol. Chem.
268,
640-644[Abstract/Free Full Text]
|
| 9.
|
Santalucia, T.,
Boheler, K. R.,
Brand, N. J.,
Sahye, U.,
Fandos, C.,
Vinals, F.,
Ferre, J.,
Testar, X.,
Palacin, M.,
and Zorzano, A.
(1999)
J. Biol. Chem.
274,
17626-17634[Abstract/Free Full Text]
|
| 10.
|
Thai, M. V.,
Guruswamy, S.,
Cao, K. T.,
Pessin, J. E.,
and Olson, A. L.
(1998)
J. Biol. Chem.
273,
14285-14292[Abstract/Free Full Text]
|
| 11.
|
Olson, A. L.,
Edgington, N. P.,
Moye-Rowley, W. S.,
and Pessin, J. E.
(1995)
Endocrinology
136,
1962-1968[Abstract]
|
| 12.
|
Michael, L. F., Wu, Z.,
Cheatham, R. B.,
Puigserver, P.,
Adelmant, G.,
Lehman, J. J.,
Kelly, D. P.,
and Spiegelman, B. M.
(2001)
Proc. Natl. Acad. Sci. U. S. A.
98,
3820-3825[Abstract/Free Full Text]
|
| 13.
|
Nuez, B.,
Michalovich, D.,
Bygrave, A.,
Ploemacher, R.,
and Grosveld, F.
(1995)
Nature
375,
316-318[CrossRef][Medline]
[Order article via Infotrieve]
|
| 14.
|
Perkins, A. C.,
Sharpe, A. H.,
and Orkin, S. H.
(1995)
Nature
375,
318-322[CrossRef][Medline]
[Order article via Infotrieve]
|
| 15.
|
Kuo, C. T.,
Veselits, M. L.,
and Leiden, J. M.
(1997)
Science
277,
1986-1990[Abstract/Free Full Text]
|
| 16.
|
Kuo, C. T.,
Veselits, M. L.,
Barton, K. P., Lu, M. M.,
Clendenin, C.,
and Leiden, J. M.
(1997)
Genes Dev.
11,
2996-3006[Abstract/Free Full Text]
|
| 17.
|
Wani, M. A.,
Means, R. T., Jr.,
and Lingrel, J. B.
(1998)
Transgenic Res.
7,
229-238[CrossRef][Medline]
[Order article via Infotrieve]
|
| 18.
|
Wani, M. A.,
Wert, S. E.,
and Lingrel, J. B.
(1999)
J. Biol. Chem.
274,
21180-21185[Abstract/Free Full Text]
|
| 19.
|
Segre, J. A.,
Bauer, C.,
and Fuchs, E.
(1999)
Nat. Genet.
22,
356-360[CrossRef][Medline]
[Order article via Infotrieve]
|
| 20.
|
Morrison, R. F.,
and Farmer, S. R.
(1999)
J. Biol. Chem.
274,
17088-17097[Abstract/Free Full Text]
|
| 21.
|
Ranganath, S.,
Ouyang, W.,
Bhattarcharya, D.,
Sha, W. C.,
Grupe, A.,
Peltz, G.,
and Murphy, K. M.
(1998)
J. Immunol.
161,
3822-3826[Abstract/Free Full Text]
|
| 22.
|
Wu, Z.,
Xie, Y.,
Morrison, R. F.,
Bucher, N. L.,
and Farmer, S. R.
(1998)
J. Clin. Invest.
101,
22-32[Medline]
[Order article via Infotrieve]
|
| 23.
|
Feinberg, M. W.,
Jain, M. K.,
Werner, F.,
Sibinga, N. E.,
Wiesel, P.,
Wang, H.,
Topper, J. N.,
Perrella, M. A.,
and Lee, M. E.
(2000)
J. Biol. Chem.
275,
25766-25773[Abstract/Free Full Text]
|
| 24.
|
Springhorn, J. P.,
and Claycomb, W. C.
(1989)
Biochem. J.
258,
73-78[Medline]
[Order article via Infotrieve]
|
| 25.
|
Collins, K. A.,
Korcarz, C. E.,
Shroff, S. G.,
Bednarz, J. E.,
Fentzke, R. C.,
Lin, H.,
Leiden, J. M.,
and Lang, R. M.
(2001)
Am. J. Physiol.
280,
H1954-H1962
|
| 26.
|
Tybulewicz, V. L.,
Crawford, C. E.,
Jackson, P. K.,
Bronson, R. T.,
and Mulligan, R. C.
(1991)
Cell
65,
1153-1163[CrossRef][Medline]
[Order article via Infotrieve]
|
| 27.
|
Kupershmidt, S.,
Yang, T.,
Anderson, M. E.,
Wessels, A.,
Niswender, K. D.,
Magnuson, M. A.,
and Roden, D. M.
(1999)
Circ. Res.
84,
146-152[Abstract/Free Full Text]
|
| 28.
|
Uchida, S.,
Tanaka, Y.,
Ito, H.,
Saitoh-Ohara, F.,
Inazawa, J.,
Yokoyama, K. K.,
Sasaki, S.,
and Marumo, F.
(2000)
Mol. Cell. Biol.
20,
7319-7331[Abstract/Free Full Text]
|
| 29.
|
Green, H.,
and Kehinde, O.
(1975)
Cell
5,
19-27[CrossRef][Medline]
[Order article via Infotrieve]
|
| 30.
|
Abel, E. D.,
Kaulbach, H. C.,
Tian, R.,
Hopkins, J. C.,
Duffy, J.,
Doetschman, T.,
Minnemann, T.,
Boers, M. E.,
Hadro, E.,
Oberste-Berghaus, C.,
Quist, W.,
Lowell, B. B.,
Ingwall, J. S.,
and Kahn, B. B.
(1999)
J. Clin. Invest.
104,
1703-1714[Medline]
[Order article via Infotrieve]
|
| 31.
|
Zorzano, A.,
Sevilla, L.,
Camps, M.,
Becker, C.,
Meyer, J.,
Kammermeier, H.,
Munoz, P.,
Guma, A.,
Testar, X.,
Palacin, M.,
Blasi, J.,
and Fischer, Y.
(1997)
Am. J. Cardiol.
80 Suppl. 3A,
65A-76A[CrossRef][Medline]
[Order article via Infotrieve]
|
| 32.
|
Yoshizumi, M.,
Lee, W. S.,
Hsieh, C. M.,
Tsai, J. C., Li, J.,
Perrella, M. A.,
Patterson, C.,
Endege, W. O.,
Schlegel, R.,
and Lee, M. E.
(1995)
J. Clin. Invest.
95,
2275-2280[Medline]
[Order article via Infotrieve]
|
| 33.
|
Paternostro, G.,
Clarke, K.,
Heath, J.,
Seymour, A. M.,
and Radda, G. K.
(1995)
Cardiovas. Res.
30,
205-211[CrossRef][Medline]
[Order article via Infotrieve]
|
| 34.
|
Charron, M. J.,
Katz, E. B.,
and Olson, A. L.
(1999)
J. Biol. Chem.
274,
3253-3256[Free Full Text]
|
| 35.
|
Shepherd, P. R.,
Gnudi, L.,
Tozzo, E.,
Yang, H.,
Leach, F.,
and Kahn, B. B.
(1993)
J. Biol. Chem.
268,
22243-22246[Abstract/Free Full Text]
|
| 36.
|
Leturque, A.,
Loizeau, M.,
Vaulont, S.,
Salminen, M.,
and Girard, J.
(1996)
Diabetes
45,
23-27[Abstract]
|
| 37.
|
Liu, M. L.,
Olson, A. L.,
Moye-Rowley, W. S.,
Buse, J. B.,
Bell, G. I.,
and Pessin, J. E.
(1992)
J. Biol. Chem.
267,
11673-11676[Abstract/Free Full Text]
|
| 38.
|
Ren, J. M.,
Marshall, B. A.,
Mueckler, M. M.,
McCaleb, M.,
Amatruda, J. M.,
and Shulman, G. I.
(1995)
J. Clin. Invest.
95,
429-432[Medline]
[Order article via Infotrieve]
|
| 39.
|
Gibbs, E. M.,
Stock, J. L.,
McCoid, S. C.,
Stukenbrok, H. A.,
Pessin, J. E.,
Stevenson, R. W.,
Milici, A. J.,
and McNeish, J. D.
(1995)
J. Clin. Invest.
95,
1512-1518[Medline]
[Order article via Infotrieve]
|
| 40.
|
El-Jack, A. K.,
Hamm, J. K.,
Pilch, P. F.,
and Farmer, S. R.
(1999)
J. Biol. Chem.
274,
7946-7951[Abstract/Free Full Text]
|
| 41.
|
Rosen, E. D.,
Walkey, C. J.,
Puigserver, P.,
and Spiegelman, B. M.
(2000)
Genes Dev.
14,
1293-1307[Free Full Text]
|
| 42.
|
Wu, Z.,
Puigserver, P.,
and Spiegelman, B. M.
(1999)
Curr. Opin. Cell Biol.
11,
689-694[CrossRef][Medline]
[Order article via Infotrieve]
|
| 43.
|
Wu, Z.,
Rosen, E. D.,
Brun, R.,
Hauser, S.,
Adelmant, G.,
Troy, A. E.,
McKeon, C.,
Darlington, G. J.,
and Spiegelman, B. M.
(1999)
Mol. Cell
3,
151-158[CrossRef][Medline]
[Order article via Infotrieve]
|
| 44.
|
Wang, N. D.,
Finegold, M. J.,
Bradley, A., Ou, C. N.,
Abdelsayed, S. V.,
Wilde, M. D.,
Taylor, L. R.,
Wilson, D. R.,
and Darlington, G. J.
(1995)
Science
269,
1108-1112[Abstract/Free Full Text]
|
| 45.
|
Banz, W. J.,
Abel, M. A.,
and Zemel, M. B.
(1996)
Horm. Metab. Res.
28,
271-275[Medline]
[Order article via Infotrieve]
|
| 46.
|
Kim, Y. C.,
and Zemel, M. B.
(1995)
Biochem. J.
311,
555-559
|
| 47.
|
Katz, E. B.,
Burlein, R.,
Tsao, T. S.,
Stenbit, A. E.,
and Charron, M. J.
(1996)
J. Mol. Med.
74,
639-652[CrossRef][Medline]
[Order article via Infotrieve]
|
| 48.
|
Kahn, B. B.
(1996)
Diabetes
45,
1644-1654[Abstract]
|
Copyright © 2002 by The American Society for Biochemistry and Molecular Biology, Inc.

CiteULike Complore Connotea Del.icio.us Digg Reddit Technorati What's this?
This article has been cited by other articles:

|
 |

|
 |
 
X. Du, R. L. Rosenfield, and K. Qin
KLF15 Is a Transcriptional Regulator of the Human 17{beta}-Hydroxysteroid Dehydrogenase Type 5 Gene. A Potential Link between Regulation of Testosterone Production and Fat Stores in Women
J. Clin. Endocrinol. Metab.,
July 1, 2009;
94(7):
2594 - 2601.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
N. Yoshikawa, M. Nagasaki, M. Sano, S. Tokudome, K. Ueno, N. Shimizu, S. Imoto, S. Miyano, M. Suematsu, K. Fukuda, et al.
Ligand-based gene expression profiling reveals novel roles of glucocorticoid receptor in cardiac metabolism
Am J Physiol Endocrinol Metab,
June 1, 2009;
296(6):
E1363 - E1373.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D. P Zobel, C. H Andreasen, K. S Burgdorf, E. A Andersson, A. Sandbaek, T. Lauritzen, K. Borch-Johnsen, T. Jorgensen, S. Maeda, Y. Nakamura, et al.
Variation in the gene encoding Kruppel-like factor 7 influences body fat: studies of 14 818 Danes
Eur. J. Endocrinol.,
April 1, 2009;
160(4):
603 - 609.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
G. A. Lima, G. F. Anhe, G. Giannocco, M. T. Nunes, M. L. Correa-Giannella, and U. F. Machado
Contractile activity per se induces transcriptional activation of SLC2A4 gene in soleus muscle: involvement of MEF2D, HIF-1a, and TR{alpha} transcriptional factors
Am J Physiol Endocrinol Metab,
January 1, 2009;
296(1):
E132 - E138.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
E. Karnieli and M. Armoni
Transcriptional regulation of the insulin-responsive glucose transporter GLUT4 gene: from physiology to pathology
Am J Physiol Endocrinol Metab,
July 1, 2008;
295(1):
E38 - E45.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. V. Autieri
Kruppel-Like Factor 4: Transcriptional Regulator of Proliferation, or Inflammation, or Differentiation, or All Three?
Circ. Res.,
June 20, 2008;
102(12):
1455 - 1457.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. L. McGee, B. J.W. van Denderen, K. F. Howlett, J. Mollica, J. D. Schertzer, B. E. Kemp, and M. Hargreaves
AMP-Activated Protein Kinase Regulates GLUT4 Transcription by Phosphorylating Histone Deacetylase 5
Diabetes,
April 1, 2008;
57(4):
860 - 867.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. Fisch, S. Gray, S. Heymans, S. M. Haldar, B. Wang, O. Pfister, L. Cui, A. Kumar, Z. Lin, S. Sen-Banerjee, et al.
Kruppel-like factor 15 is a regulator of cardiomyocyte hypertrophy
PNAS,
April 24, 2007;
104(17):
7074 - 7079.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
I J Bujalska, M Quinkler, J W Tomlinson, C T Montague, D M Smith, and P M Stewart
Expression profiling of 11{beta}-hydroxysteroid dehydrogenase type-1 and glucocorticoid-target genes in subcutaneous and omental human preadipocytes.
J. Mol. Endocrinol.,
October 1, 2006;
37(2):
327 - 340.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
H. Das, A. Kumar, Z. Lin, W. D. Patino, P. M. Hwang, M. W. Feinberg, P. K. Majumder, and M. K. Jain
Kruppel-like factor 2 (KLF2) regulates proinflammatory activation of monocytes
PNAS,
April 25, 2006;
103(17):
6653 - 6658.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
Y. Kawamura, Y. Tanaka, R. Kawamori, and S. Maeda
Overexpression of Kruppel-Like Factor 7 Regulates Adipocytokine Gene Expressions in Human Adipocytes and Inhibits Glucose-Induced Insulin Secretion in Pancreatic {beta}-Cell Line
Mol. Endocrinol.,
April 1, 2006;
20(4):
844 - 856.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. Baudry, Z.-Z. Yang, and B. A. Hemmings
PKB{alpha} is required for adipose differentiation of mouse embryonic fibroblasts
J. Cell Sci.,
March 1, 2006;
119(5):
889 - 897.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. W. Feinberg, Z. Cao, A. K. Wara, M. A. Lebedeva, S. SenBanerjee, and M. K. Jain
Kruppel-like Factor 4 Is a Mediator of Proinflammatory Signaling in Macrophages
J. Biol. Chem.,
November 18, 2005;
280(46):
38247 - 38258.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. J. Sullivan, T. H. Teal, I. P. Luttrell, K. B. Tran, M. A. Peters, and H. Wessells
Microarray analysis reveals novel gene expression changes associated with erectile dysfunction in diabetic rats
Physiol Genomics,
October 17, 2005;
23(2):
192 - 205.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
T. Y. Kostrominova, D. E. Dow, R. G. Dennis, R. A. Miller, and J. A. Faulkner
Comparison of gene expression of 2-mo denervated, 2-mo stimulated-denervated, and control rat skeletal muscles
Physiol Genomics,
July 14, 2005;
22(2):
227 - 243.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
T. Suzuki, K. Aizawa, T. Matsumura, and R. Nagai
Vascular Implications of the Kruppel-Like Family of Transcription Factors
Arterioscler. Thromb. Vasc. Biol.,
June 1, 2005;
25(6):
1135 - 1141.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. D. Moyes and C. M. R. LeMoine
Control of muscle bioenergetic gene expression: implications for allometric scaling relationships of glycolytic and oxidative enzymes
J. Exp. Biol.,
May 1, 2005;
208(9):
1601 - 1610.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
T. Mori, H. Sakaue, H. Iguchi, H. Gomi, Y. Okada, Y. Takashima, K. Nakamura, T. Nakamura, T. Yamauchi, N. Kubota, et al.
Role of Kruppel-like Factor 15 (KLF15) in Transcriptional Regulation of Adipogenesis
J. Biol. Chem.,
April 1, 2005;
280(13):
12867 - 12875.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D. C. Otteson, Y. Liu, H. Lai, C. Wang, S. Gray, M. K. Jain, and D. J. Zack
Kruppel-like Factor 15, a Zinc-Finger Transcriptional Regulator, Represses the Rhodopsin and Interphotoreceptor Retinoid-Binding Protein Promoters
Invest. Ophthalmol. Vis. Sci.,
August 1, 2004;
45(8):
2522 - 2530.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. Yamamoto, Y. Ikeda, H. Iguchi, T. Fujino, T. Tanaka, H. Asaba, S. Iwasaki, R. X. Ioka, I. W. Kaneko, K. Magoori, et al.
A Kruppel-like factor KLF15 Contributes Fasting-induced Transcriptional Activation of Mitochondrial Acetyl-CoA Synthetase Gene AceCS2
J. Biol. Chem.,
April 23, 2004;
279(17):
16954 - 16962.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. W. Feinberg, M. Watanabe, M. A. Lebedeva, A. S. Depina, J.-i. Hanai, T. Mammoto, J. P. Frederick, X.-F. Wang, V. P. Sukhatme, and M. K. Jain
Transforming Growth Factor-{beta}1 Inhibition of Vascular Smooth Muscle Cell Activation Is Mediated via Smad3
J. Biol. Chem.,
April 16, 2004;
279(16):
16388 - 16393.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. B. Knight, C. A. Eyster, B. A. Griesel, and A. L. Olson
Regulation of the human GLUT4 gene promoter: Interaction between a transcriptional activator and myocyte enhancer factor 2A
PNAS,
December 9, 2003;
100(25):
14725 - 14730.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
H. Moreno, A. L. Serrano, T. Santalucia, A. Guma, C. Canto, N. J. Brand, M. Palacin, S. Schiaffino, and A. Zorzano
Differential Regulation of the Muscle-specific GLUT4 Enhancer in Regenerating and Adult Skeletal Muscle
J. Biol. Chem.,
October 17, 2003;
278(42):
40557 - 40564.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. S. Banerjee, M. W. Feinberg, M. Watanabe, S. Gray, R. L. Haspel, D. J. Denkinger, R. Kawahara, H. Hauner, and M. K. Jain
The Kruppel-like Factor KLF2 Inhibits Peroxisome Proliferator-activated Receptor-gamma Expression and Adipogenesis
J. Biol. Chem.,
January 17, 2003;
278(4):
2581 - 2584.
[Abstract]
[Full Text]
[PDF]
|
 |
|
Copyright © 2002 by the American Society for Biochemistry and Molecular Biology.
|
Advertisement
Advertisement
|